Want to see SE:SPEC full AI Analyst Report?

SpectraCure AB (SPEC) Price & Analysis

1 Followers

SPEC Stock Chart & Stats

kr0.18

kr0.10(5.82%)

At close: Mar 06 4:00 PM EST

kr0.18

kr0.10(5.82%)

Day’s Range― - ―

52-Week Rangekr0.03 - kr0.24

Previous CloseN/A

Volume60.95K

Average Volume (3M)1.15M

Market Cap

kr66.76M

Enterprise Valuekr49.94

Total Cash (Recent Filing)kr16.59M

Total Debt (Recent Filing)kr2.19M

Price to Earnings (P/E)―

Beta-0.06

Next Earnings

Nov 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.19

Shares Outstanding1,711,808,500

10 Day Avg. Volume1,242,664

30 Day Avg. Volume1,152,681

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)0.68

Price to Sales (P/S)0.00

P/FCF Ratio-1.46

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Financial LeverageVery low leverage reduces near-term solvency pressure and preserves financial flexibility while the company develops its platform. This gives management more room to fund clinical and commercial progress without the constraints typically associated with material debt obligations.

Targeted PDT PlatformA minimally invasive therapy platform with real-time treatment monitoring could provide a differentiated clinical proposition if validated and adopted. Its initial focus on prostate cancer also gives the company a defined application area for clinical development and commercialization.

Recurring Procedure Revenue PotentialA deployed treatment system paired with procedure-specific consumables could create recurring revenue per clinical use, improving lifetime economics beyond one-time equipment sales. This model may support operating leverage if adoption expands, although commercial scale is not yet demonstrated.

Bears Say

Negligible Revenue BaseThe absence of meaningful revenue shows that the platform has not yet achieved commercial scale. Until clinical adoption, regulatory progress and reimbursement translate into sales, the company remains exposed to execution risk and lacks an established operating revenue base.

Persistent And Widening LossesLarge, persistent losses despite negligible revenue indicate that operating costs are not being absorbed by commercial activity. Continued losses could require additional funding and may limit the company’s ability to invest in development, regulatory work and market expansion.

Sustained Cash BurnNegative operating and free cash flow means the business is not self-funding and remains dependent on external financing. If cash generation does not improve, repeated fundraising may dilute existing holders and create execution risk around the platform’s development.

SPEC FAQ

What was SpectraCure AB’s price range in the past 12 months?

SpectraCure AB lowest stock price was kr0.03 and its highest was kr0.24 in the past 12 months.

What is SpectraCure AB’s market cap?

SpectraCure AB’s market cap is kr66.76M.

When is SpectraCure AB’s upcoming earnings report date?

SpectraCure AB’s upcoming earnings report date is Nov 13, 2026 which is in 79 days.

How were SpectraCure AB’s earnings last quarter?

SpectraCure AB released its earnings results on Aug 21, 2026. The company reported -kr0.006 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is SpectraCure AB overvalued?

According to Wall Street analysts SpectraCure AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does SpectraCure AB pay dividends?

SpectraCure AB does not currently pay dividends.

What is SpectraCure AB’s EPS estimate?

SpectraCure AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does SpectraCure AB have?

SpectraCure AB has 1,711,808,500 shares outstanding.

What happened to SpectraCure AB’s price movement after its last earnings report?

SpectraCure AB reported an EPS of -kr0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.405%.

Which hedge fund is a major shareholder of SpectraCure AB?

Currently, no hedge funds are holding shares in SE:SPEC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

SpectraCure AB

SpectraCure AB (publ) specializes in oncology, developing innovative cancer treatments that harness laser light and photodynamic agents. A cornerstone of their research is the IDOSE software, which powers an interstitial photodynamic therapy (PDT) system. This cutting-edge system is currently in Phase II clinical trials, where its efficacy in addressing solid tumors is being evaluated. The Swedish company, established in Lund in 2003, continues to advance its therapeutic solutions.